BRPI0717306A2 - COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD OF TREATMENT, PREVENTION OR RELIEF OF A DISEASE OR DISORDER OR CONDITION OF A LIVE BODY. - Google Patents
COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD OF TREATMENT, PREVENTION OR RELIEF OF A DISEASE OR DISORDER OR CONDITION OF A LIVE BODY.Info
- Publication number
- BRPI0717306A2 BRPI0717306A2 BRPI0717306-7A2A BRPI0717306A BRPI0717306A2 BR PI0717306 A2 BRPI0717306 A2 BR PI0717306A2 BR PI0717306 A BRPI0717306 A BR PI0717306A BR PI0717306 A2 BRPI0717306 A2 BR PI0717306A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disorder
- relief
- disease
- prevention
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200601380 | 2006-10-25 | ||
| PCT/EP2007/061433 WO2008049864A1 (en) | 2006-10-25 | 2007-10-24 | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0717306A2 true BRPI0717306A2 (en) | 2014-04-15 |
Family
ID=40996458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717306-7A2A BRPI0717306A2 (en) | 2006-10-25 | 2007-10-24 | COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD OF TREATMENT, PREVENTION OR RELIEF OF A DISEASE OR DISORDER OR CONDITION OF A LIVE BODY. |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR20090069183A (en) |
| CN (1) | CN101553486A (en) |
| BR (1) | BRPI0717306A2 (en) |
| NZ (1) | NZ575354A (en) |
| RU (1) | RU2009113451A (en) |
| UA (1) | UA99443C2 (en) |
| ZA (1) | ZA200901521B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2563113T3 (en) * | 2011-02-25 | 2016-03-10 | Janssen Pharmaceutica, N.V. | (Pyridin-4-yl) benzylamides as allosteric modulators of nAChR alpha 7 |
| CN103420998A (en) * | 2012-05-16 | 2013-12-04 | 苏州爱斯鹏药物研发有限责任公司 | Synthesis method of novel oxadiazoles derivative |
| CN111362930B (en) * | 2020-04-15 | 2023-02-03 | 安徽医科大学 | 1,2,4-oxadiazole-pyridine compound and application thereof |
-
2007
- 2007-10-24 ZA ZA200901521A patent/ZA200901521B/en unknown
- 2007-10-24 UA UAA200903386A patent/UA99443C2/en unknown
- 2007-10-24 NZ NZ575354A patent/NZ575354A/en not_active IP Right Cessation
- 2007-10-24 RU RU2009113451/04A patent/RU2009113451A/en not_active Application Discontinuation
- 2007-10-24 BR BRPI0717306-7A2A patent/BRPI0717306A2/en not_active IP Right Cessation
- 2007-10-24 CN CNA2007800391836A patent/CN101553486A/en active Pending
- 2007-10-24 KR KR1020097008536A patent/KR20090069183A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009113451A (en) | 2010-11-27 |
| CN101553486A (en) | 2009-10-07 |
| KR20090069183A (en) | 2009-06-29 |
| NZ575354A (en) | 2012-05-25 |
| ZA200901521B (en) | 2010-06-30 |
| UA99443C2 (en) | 2012-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0820568A2 (en) | Compound, pharmaceutical composition, use of a compound or pharmaceutical composition, and method of treating a human or animal | |
| BRPI0717697A2 (en) | compound, pharmaceutical composition, use of the compound, method of treating a patient suffering from a pathological condition or disease and combination of products | |
| BRPI0812740A2 (en) | compound, pharmaceutical composition, use of the compound, and method for treating, preventing or alleviating a central nervous system disorder of a living animal body. | |
| BRPI0717219A2 (en) | "immunogenic composition, method for treating or preventing disease, and use of an immunogenic composition." | |
| BRPI0817525A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATMENT, CONTROL OR PREVENTION OF A DISEASE OR DISORDER. | |
| BRPI0909768A2 (en) | compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by activation of b3-adrenoceptor, and use of a compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by b3-adrenoceptor. b3-adrenoceptor activation, and use of a compound | |
| BRPI0911203A2 (en) | peptide or peptide derivative, pharmaceutical composition, use of a peptide or peptide derivative, methods for treating a patient having a deficiency and for preparing the peptide or peptide derivative. | |
| BRPI0819799A2 (en) | Compound, intermediate, use of a compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease | |
| BRPI1009860A2 (en) | compound, use thereof, pharmaceutical composition and method for the therapeutic treatment or prevention of disease in humans or animals | |
| BRPI0917458A2 (en) | compound, method of treating disease and conditions, pharmaceutical composition, method for treating or preventing disease, and use of a compound | |
| BR112012003464A2 (en) | compound, pharmaceutical composition, uses of a pharmaceutical composition and a compound, and method for treating a disease or disorder. " | |
| EP1824442A4 (en) | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L. | |
| BRPI0907977A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
| BRPI0917138A2 (en) | compound, methods for treating allergic diseases and other inflammatory conditions, allergic rhinitis, and for treating or preventing disease, pharmaceutical composition, use of a compound, and combination. | |
| BRPI0917705A2 (en) | compound, prodrug, pharmaceutical composition, method for treating or preventing a disease or condition, and use of the compound | |
| BRPI0815591A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREATING A DISEASE, CONDITION OR DISTURBANCE. | |
| BRPI0717753A2 (en) | METHOD OF TREATING OR REDUCING THE RISK OF A DISEASE CAUSED BY PROTOZOAN AND, COMPOSITION. | |
| BRPI0817063A2 (en) | "Inhibition methods, for treatment of a pathological condition, for inhibition of tumor lymphagenesis, for inhibition or prevention, for disorganization, for inhibition of tumor growth, for treatment, for enhancing the efficacy of an anti-angiogenesis and antagonist agent" from alk-1 | |
| BRPI0905687A2 (en) | "compound of formula i or i ', pharmaceutical composition, method of treating a patient with a disease, use of the compound" | |
| BRPI0913854A2 (en) | compound, pharmaceutical composition, use of the compound, and, method for treating, preventing or alleviating a disease or disorder or condition of a living animal organism. | |
| BRPI0908124A2 (en) | Compound, glucokinase activator, pharmaceutical composition, use of a pharmaceutically acceptable salt or compound thereof, and methods of activating glucokinase, and to treat and / or prevent a disease. | |
| BRPI0907974A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
| BRPI0713447A2 (en) | solid oral dosage form composition, and, method for treating pain | |
| BRPI0807285A2 (en) | "COMPOSITION, METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION, UNIT FORM OF DOSAGE, METHOD FOR ADMINISTRATING A BIOLOGICAL ACTIVE AGENT NEEDING THE AGENT, METHOD FOR INCREASING BIODISPONABILITY FOR PREPARING AN AGENT OF COMPOSITION" | |
| BRPI0911197A2 (en) | compound, peroxisome proliferator-activated receptor activator, and, medicament for the treatment and / or prophylaxis of a disease. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 6A E 7A ANUIDADES. |
|
| B08I | Application fees: publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |